Tag: HER2
-
Jazz Wins First-Line FDA Approval for Ziihera in HER2-Positive Gastroesophageal Cancer
The FDA approved Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma, strengthening Jazz Pharmaceuticals’ solid-tumor oncology strategy.
-
How Ziihera Targets HER2 Differently From Trastuzumab
Ziihera binds two HER2 extracellular domains simultaneously, promoting receptor internalization and immune-mediated killing through a mechanism distinct from trastuzumab and Enhertu.